Europe’s drug regulators on Thursday recommended approval of thalidomide to treat bone marrow cancer, nearly 50 years after the medicine was withdrawn as a treatment for morning sickness around the world because it caused thousands of children to be born with birth defects.

The European medicines agency granted authorisation for the medicine to be used to treat multiple myeloma in combination with other drugs, on condition that it was strictly controlled to avoid it being taken by pregnant women.